Clinical Trials
2.9k
Active:472
Completed:1181
Trial Phases
6 Phases
Early Phase 1:76
Phase 1:721
Phase 2:1004
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2412 trials with phase data)β’ Click on a phase to view related trials
Phase 2
1004 (41.6%)Phase 1
721 (29.9%)Not Applicable
480 (19.9%)Phase 3
102 (4.2%)Early Phase 1
76 (3.2%)Phase 4
29 (1.2%)Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
Not Applicable
Not yet recruiting
- Conditions
- Phase II Clinical TrialBlinatumomabOlverembatinibLymphoblastic LeukemiaPhiladelphia Chromosome Positive
- Interventions
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07178912
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT07169825
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Not Applicable
Not yet recruiting
- Conditions
- Large B-cell LymphomaHodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT07164469
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their Caregivers
Not Applicable
Not yet recruiting
- Conditions
- Family CenteredBlack EthnicityProstate Cancer Survivors
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 648
- Registration Number
- NCT07164456
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
Not Applicable
Not yet recruiting
- Conditions
- Adenoid Cystic Carcinoma
- Interventions
- Drug: P-Sam
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT07162480
- Locations
- πΊπΈ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 582
- Next
News
No news found